NCT03566134View on ClinicalTrials.gov

A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder

PHASE2CompletedINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

July 10, 2018

Primary Completion Date

December 27, 2019

Study Completion Date

December 27, 2019

Conditions
Overactive Bladder
Interventions
DRUG

DA-8010 Placebo

Participants receive placebo to match DA-8010 orally once a day.

DRUG

DA-8010 2.5mg

Participants receive DA-8010 2.5mg orally once a day.

DRUG

DA-8010 5mg

Participants receive DA-8010 5mg orally once a day.

DRUG

Solifenacin 5mg

Participants receive solifenacin 5 mg orally once a day.

DRUG

Solifenacin succinate placebo

Participants receive placebo to match solifenacin 5 mg orally once a day.

Trial Locations (1)

Unknown

Severance Hospital, Seoul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT03566134 - A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder | Biotech Hunter | Biotech Hunter